Radiotherapy With Hyperthermia for Prostatic Ductal Adenocarcinoma: Primary and Salvage Cases Authors: YASUAKI MATSUURA, DAISUKE NAKAYA, SUBARU TANI, SHOHEI SHIMAJIRI, NAOHIRO FUJIMOTO, TAKAYUKI OHGURI Published: 2026 ABSTRACT Background/AimProstatic ductal adenocarcinoma (PDA) is a rare and aggressive histological variant of prostate cancer associated with a high risk of treatment failure and poor survival compared to conventional acinar adenocarcinoma. We report three cases of PDA treated with radiotherapy combined with regional hyperthermia.Case ReportTwo patients with locally advanced PDA (cT3aN0M0) were treated with definitive intensity-modulated radiotherapy combined with regional hyperthermia. One patient with biochemical recurrence following radical prostatectomy (pT3aN0M0) received salvage three-dimensional conformal radiotherapy with regional hyperthermia. Therapeutic heating was achieved in all cases, with thermal doses (CEM43T90) of 5.2, 6.1, and 2.3 min, respectively. Long-term clinical control was observed in all patients, with follow-up durations of six, nine, and eight years, respectively. In the salvage case, a secondary prostate-specific antigen increase occurred but was successfully controlled with short-term hormonal therapy, with no subsequent clinical progression.ConclusionRadiotherapy combined with regional hyperthermia may represent a promising treatment strategy for achieving durable clinical control in patients with PDA. Introduction Prostatic ductal adenocarcinoma (PDA) is an uncommon histological entity, representing approximately 0.4% to 0.8% of all primary prostate malignancies. Histologically, it is distinguished by tall, pseudostratified columnar epithelium forming complex papillary and cribriform patterns, which differ significantly from the small, uniform acinar structures of conventional adenocarcinoma (1). Clinically, PDA frequently presents as a bulky, periurethral mass that protrudes into the bladder neck or urethra, often leading to early obstructive symptoms and hematuria. A hallmark of this variant is its aggressive biological behavior; despite substantial local tumor volumes, PDA often exhibits disproportionately low serum prostate-specific antigen (PSA) secretion, which may lead to understaging and delayed therapeutic intervention (2). While definitive or salvage radiotherapy (RT) is an established treatment for prostate cancer, the optimal intensification strategy for the ductal variant remains a subject of investigation (3-5). The complex architecture and rapid growth of PDA can create hypoxic microenvironments, contributing to intrinsic radioresistance. Regional hyperthermia (HT) is a potent radiosensitizer that enhances the efficacy of ionizing radiation by increasing microvascular blood flow and exerting direct cytotoxic effects (5-7). In this report, we describe the long-term clinical outcomes of three patients with locally advanced or recurrent PDA treated with a combination of RT and regional HT. Case Report Case 1. An octogenarian male presented with gross hematuria and subsequent acute urinary retention due to bladder tamponade. Upon physical examination, a large, firm mass was palpated in the prostate region. Computed tomography (CT) imaging revealed a bulky, irregular tumor measuring approximately 65 mm in its maximum diameter, extending toward the bladder neck and proximal prostatic urethra without definite bladder wall invasion, consistent with clinical stage cT3aN0M0 (Figure 1). Despite this burden, the initial PSA was 6.7 ng/ml. Pathological examination via transurethral resection (TURP) confirmed pure prostatic ductal adenocarcinoma with a Gleason score of 4+4. The treatment regimen included maximum androgen blockade followed by intensity-modulated radiotherapy (IMRT) to a total dose of 76 Gy in 38 fractions. Concurrently, regional HT (Thermotron RF-8, Yamamoto Vinita Co., Ltd., Osaka, Japan) was administered once weekly for five sessions using 25-cm-diameter electrodes. Thermal dosimetry using an intrarectal probe demonstrated a thermal dose (cumulative equivalent minutes at 43°C for T90; CEM43T90) of 5.2 min over five sessions. Following treatment, the PSA level declined to an undetectable level (<0.008 ng/ml). At the 72-month follow-up, the patient remains in biochemical and clinical control without late toxicities. Case 1 (cT3aN0M0, prostatic ductal adenocarcinoma). A) Transurethral resection findings showing a bulky, papillary tumor mass protruding into the prostatic urethra and bladder neck, characteristic of the ductal variant. B) Pre-treatment computed tomography imaging revealing an irregular hypointense mass. A urinary balloon catheter is seen inserted within the prostatic urethra. C) Low-power view of a TURP specimen showing complex and irregular glandular proliferation. D) High-power view demonstrating atypical glandular epithelial cells with tall columnar morphology, hyperchromatic nuclei, and pseudostratified architecture forming papillary and distorted glandular structures. E) Intensity modulated radiation therapy plan displaying the delivery of 76 Gy to the target volume. F) Temperature data were recorded at five distinct points using a multi-point thermocouple sensor. These included four intrarectal points corresponding to the posterior aspect of the prostate located at 7.0 cm, 5.5 cm, 4.0 cm, and 2.5 cm from the anal verge, as well as one additional point located on the anal skin surface. The solid blue shaded area represents the radiofrequency power output over the course of the treatment session, corresponding to the vertical axis on the left in Watts (W). Stable therapeutic temperatures ranging between 40.5°C and 41.8°C were maintained after the initial ramp-up phase. Case 2. A septuagenarian male was referred for a large bladder mass and obstructive symptoms, with a PSA of 68.3 ng/ml. CT imaging demonstrated a central prostatic tumor with extracapsular extension and protrusion into the bladder lumen, without evidence of bladder wall invasion (cT3aN0M0) (Figure 2). TURP identified a mixed adenocarcinoma consisting of 60% ductal and 40% acinar components (Gleason score 3+4). Following six months of neoadjuvant androgen deprivation therapy (ADT), he received IMRT to a total dose of 76 Gy in 38 fractions, along with five weekly sessions of regional HT. Thermal dosimetry demonstrated a CEM43T90 of 6.1 min over five sessions. The PSA level reached a nadir of <0.01 ng/ml post-treatment. The patient has maintained long-term biochemical and clinical control for 108 months. The only morbidity was intermittent Grade 1 rectal bleeding, which resolved spontaneously without intervention. Case 2 (cT3aN0M0 mixed prostatic ductal adenocarcinoma). A) Pre-treatment axial contrast-enhanced computed tomography image showing a markedly enlarged prostate with a massive exophytic tumor mass protruding into the bladder lumen, a hallmark clinical presentation of the ductal variant. B) Endoscopic appearance of prostatic ductal adenocarcinoma. Cystoscopic view demonstrating a large, exophytic, papillary tumor occupying the prostatic urethra. C) Low-power view of the transurethral resection of the prostate specimen demonstrating extensive papillary and irregular glandular proliferation with complex architecture. D) High-power view showing markedly atypical columnar epithelial cells with hyperchromatic nuclei and pseudostratified arrangement, forming papillary and irregular glandular structures. E) Intensity modulated radiation therapy planning: axial dose distribution map illustrating the delivery of a definitive 76 Gy dose. F) Real-time thermal and power monitoring: Thermal profiles during a regional hyperthermia session. Temperatures (°C) were measured at five points, including four intrarectal locations (7.0, 5.5, 4.0, and 2.5 cm from the anal verge) and one on the anal skin. The blue shaded area represents the radiofrequency power output (Watts) required to maintain steady-state therapeutic temperatures between 40°C and 41°C. Case 3. A patient in his early 60s had undergone radical prostatectomy and was histologically diagnosed with PDA (pathological stage T3aN0M0, Gleason score 4+4, and the initial PSA of 7.2 ng/ml) (Figure 3). Following radical prostatectomy, the PSA level decreased to 0.02 ng/ml; however, biochemical recurrence was subsequently identified based on two consecutive rises in PSA levels to 0.23 and 0.27 ng/ml at approximately three years and eight months after surgery. He then received salvage three-dimensional conformal RT (3DCRT), delivering a total dose of 66 Gy in 33 fractions to the prostate bed. This treatment was combined with five sessions of regional HT using the Thermotron RF-8 system. Thermal dosimetry demonstrated a CEM43T90 of 2.3 min over five sessions. Following this combined treatment, the PSA level decreased to below 0.1 ng/ml and remained stable. Three years and three months after the completion of the combined treatments, a PSA increase to 0.22 ng/ml was observed, exceeding the threshold for biochemical recurrence, although based on a single measurement. The patient was then treated with an LH-RH agonist for a duration of six months. After six months of LH-RH agonist therapy, the PSA level decreased to <0.006 ng/ml and has remained stable at this level without further increase. Currently, more than 8 years have passed since salvage 3DCRT plus regional HT, and the patient has remained free from further biochemical recurrence and clinical progression, with no significant late toxicities. Case 3 (biochemical recurrence following radical prostatectomy). A) Low-power view showing complex glandular and papillary proliferation within the radical prostatectomy specimen, forming irregular and densely packed glandular structures. B) High-power view demonstrating atypical glandular epithelial cells with tall columnar morphology, hyperchromatic nuclei, and pseudostratified arrangement lining the glandular lumina. C) Axial salvage three-dimensional conformal radiotherapy (3DCRT) planning map delivering 66 Gy to the prostate bed. D) Temperature distribution; temperature (°C) was recorded at five points including four intrarectal locations (7.0, 5.5, 4.0, and 2.5 cm from the anal verge) and one on the anal skin, with the blue shaded area representing the power output (W). Stable therapeutic temperatures (40-41.5°C) were maintained throughout the session to enhance the efficacy of the salvage treatment. Discussion To our knowledge, this is the first report to describe durable long-term clinical control of PDA across primary and salvage settings using combined RT and regional HT. The clinical management of PDA requires potent local control to mitigate its high risk of recurrence. While large-scale studies have consistently reported poor clinical outcomes for PDA compared to acinar adenocarcinoma, with more than a twofold increased risk of cancer-specific mortality, our three cases with locally advanced and recurrent disease demonstrate long-term clinical control (2, 3). This contrast highlights the potential of combining RT and regional HT to improve the clinical course of this aggressive variant. Despite the small sample size, our results underscore the clinical value of integrating regional HT into both primary and salvage RT as a potential treatment option for PDA. Notably, these three cases represent all patients with PDA who underwent definitive or salvage RT at our institution during the study period, reflecting the rarity of this histological subtype. Biologically, PDA is characterized by its aggressive nature and bulky growth patterns, which frequently lead to the development of intratumoral hypoxia (1). Hypoxia is a well-documented driver of radioresistance and treatment failure. These hypoxic regions are significantly more resistant to RT than oxygenated tissues. HT at 40-42°C increases microvascular blood flow, which reoxygenates these radioresistant fractions and enhances the indirect effects of ionizing radiation (8, 9). Furthermore, HT exerts direct cytotoxic effects preferentially on cells in hypoxic and acidic microenvironments, where ionizing radiation is less effective. In our series, the achievement of therapeutic heating likely contributed to overcoming the inherent radioresistance of PDA, facilitating the durable local control observed even in locally advanced cases. The achievement of relatively high thermal doses (CEM43T90 >5 min) in Cases 1 and 2 appears to be a key predictor of these favorable outcomes. These findings are consistent with previous clinical evidence demonstrating the importance of thermal dose in determining treatment outcomes. In a retrospective study of 82 patients with high-risk prostate cancer treated with RT plus regional HT, higher thermal doses, defined as CEM43T90 values of more than 1 min per session, were identified as significant prognostic factors for improved biochemical disease-free survival without increasing toxicity (10). From a radiobiological perspective, the clinical impact of HT can be quantified as an equivalent dose escalation within the linear-quadratic model. Research by Kok et al. demonstrated that adding HT to a 76 Gy RT regimen for prostate cancer can increase the equivalent biological dose to approximately 86 Gy, with values exceeding 90 Gy in certain regions (11). This substantial biological dose enhancement, acting as a biological intensifier, is consistent with the durable long-term tumor control observed in our patients. The safety and feasibility of combining salvage RT and regional HT have been validated in a prospective Phase II trial involving 50 patients with recurrent prostate cancer after radical prostatectomy; moderate dose-escalated salvage RT with locoregional deep HT was well tolerated, with no acute Grade ≥3 toxicities (12). Case 3 represents a salvage setting following biochemical recurrence after radical prostatectomy. Despite the known radioresistant nature of recurrent disease and the use of conventional 3DCRT, durable clinical control was achieved for more than eight years. Physiologically, regional HT between 40°C and 42°C, often referred to as mild HT, has been shown to increase tumor blood flow and oxygenation (9). Unlike higher temperatures that may cause vascular stasis, mild HT can enhance the oxygen microenvironment, thereby potentially sensitizing hypoxic tumor cells to ionizing radiation. In Case 3, while the CEM43T90 of 2.3 min was relatively low, stable therapeutic temperatures between 40°C and 41.5°C were maintained. This suggests that the achieved mild HT likely promoted reoxygenation within the postoperative prostate bed, potentially compensating for the RT limitations in scarred tissues and contributing to the favorable 8-year clinical outcome. This observation suggests that the addition of regional HT may help overcome treatment resistance even in the postoperative recurrent setting, where tumor hypoxia and compromised vascularity are expected to be more pronounced. Conclusion RT combined with regional HT may represent a well-tolerated treatment strategy for both locally advanced and recurrent PDA. This approach may contribute to durable clinical control in this rare but aggressive disease entity. Further studies with larger cohorts and comparative data are required to clarify the contribution of regional HT to the long-term control of PDA. Conflicts of Interest The Authors have no conflicts of interest to declare in relation to this study. Authors’ Contributions YM, SS, and TO contributed to conceptualization, manuscript writing, and data curation. DN, ST, and NF contributed to clinical management, critical review, and supervision. Artificial Intelligence (AI) Disclosure During the preparation of this manuscript, a large language model [ChatGPT (OpenAI, San Francisco, CA, USA] was used solely for language editing and stylistic improvements in select paragraphs. No sections involving the generation, analysis, or interpretation of research data were produced by generative AI. All scientific content was created and verified by the authors. Furthermore, no figures or visual data were generated or modified using generative AI or machine learning-based image enhancement tools.